Therefore, the inhibition of BTK represents an attractive potential therapeutic approach for the treatment of immunological disorders such as RA or systemic lupus erythematosus (SLE) (15–20), in which B cells and myeloid cells induce or sustain an excessive autoimmune response. The gene discussed is BTK; the disease is systemic lupus erythematosus.